EUVIMEDEUVIMED entdecken
Crossref

Antitumor potential of anti-glycosphingolipid therapy

Svetlana A. Kulyova, Vadim A. Khashuro, Ekaterina G. Batocirenova, Gaziя A. Sachautdinov, Yulia K. Semenova, Maria M. Vasilyeva, Alika A. Kulyova, Olga E. Savyelyeva

Annals of the Russian academy of medical sciences · 16.05.2026 · 81 (1) · 30-40

DOI: 10.15690/vramn18038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of the Russian academy of medical sciences, online erschienen am 16.05.2026. Verfasst von Svetlana A. Kulyova und 7 weiteren Autor:innen. Die Arbeit nennt 76 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Currently, immuno-oncology is a rapidly developing field of medicine, primarily due to the integration of achievements in molecular biology and biotechnology (creation and production of modified cells and effector molecules), immunological physiology (understanding of subtle mechanisms of regulation of immune functions) and clinical medicine (adequate accompanying therapy, allowing manipulation of the patient’s immune system). A large number of tumors overexpress tumor-associated gangliosides (sialylated glycosphingolipids). For example, GD3, GD2 and GM2 are overexpressed in melanoma and neuroblastoma cells, increased expression of GD1a, GM1, GM2 is shown in carcinoma cells, GD2 is expressed by soft tissue sarcoma, osteogenic sarcoma and small cell lung cancer cells. The ratio of the number of gangliosides varies from one tumor type to another. In addition, gangliosides are found in neoplastic tissues that are not characteristic of normal transformed cells of this tissue. In particular, one such ganglioside is GD2. In normal cells, the expression of this ganglioside, as well as that of GM2, is restricted to nerve cells, but in the case of cancer transformation they are found in cells of malignant tumors. Numerous studies have shown that tumor-associated gangliosides arising from oncogenic transformation play a key role in invasion and metastasis of a number of tumors and induce tumor-associated angiogenesis. First of all, it has been established that tumor cells differ in the composition of gangliosides. the ganglioside composition of metastasis cells differs from the cells of the primary tumor focus and is characterized by a decrease in the content of complex gangliosides. Due to its high level of expression in a number of tumors and limited expression in normal tissues, ganglioside GD2 can be considered as an ideal potential target for the development of anti-tumor immunotherapies.

Zitieren

APA

Kulyova, S. A., Khashuro, V. A., Batocirenova, E. G., Sachautdinov, G. A., Semenova, Y. K., Vasilyeva, M. M., Kulyova, A. A., & Savyelyeva, O. E. (2026). Antitumor potential of anti-glycosphingolipid therapy. Annals of the Russian academy of medical sciences, 81(1), 30-40. https://doi.org/10.15690/vramn18038

Vancouver

Kulyova SA, Khashuro VA, Batocirenova EG, Sachautdinov GA, Semenova YK, Vasilyeva MM, et al. Antitumor potential of anti-glycosphingolipid therapy. Annals of the Russian academy of medical sciences. 2026;81(1):30-40. doi:10.15690/vramn18038

BibTeX
@article{Kulyova2026,
  author = {Kulyova, Svetlana A. and Khashuro, Vadim A. and Batocirenova, Ekaterina G. and Sachautdinov, Gaziя A. and Semenova, Yulia K. and Vasilyeva, Maria M. and Kulyova, Alika A. and Savyelyeva, Olga E.},
  title = {Antitumor potential of anti-glycosphingolipid therapy},
  journal = {Annals of the Russian academy of medical sciences},
  year = {2026},
  volume = {81},
  number = {1},
  pages = {30--40},
  doi = {10.15690/vramn18038}
}
Kostenlos starten →